| Current assets: |
| Cash and cash equivalents |
| Investments |
| Accounts receivable |
69.63M |
| Inventories |
81.16M |
| Deferred tax assets, net |
0 |
| Income tax receivable, net |
11.83M |
| Restricted cash |
| Prepaid expenses and other current assets |
18.44M |
| Total current assets |
480M |
| Property, plant and equipment, net |
362.54M |
| In-process research and development |
0 |
| Goodwill |
41M |
| Assets held for sale |
| Deferred tax assets, net |
11.29M |
| Other assets |
1.78M |
| Total assets |
932.03M |
| Current liabilities: |
| Accounts payable |
46.34M |
| Accrued expenses and other current liabilities |
4.28M |
| Accrued compensation |
32.1M |
| Contingent value rights, current portion |
| Long-term indebtedness, current portion |
| Deferred revenue, current portion |
4.82M |
| Total current liabilities |
110.31M |
| Contingent value rights, net of current portion |
| Long-term indebtedness, net of current portion |
247.79M |
| Deferred revenue, net of current portion |
4.7M |
| Other liabilities |
1.44M |
| Total liabilities |
384.4M |
| Commitments and contingencies |
0 |
| Stockholders' equity: |
| Preferred stock, $0.001 par value; 15,000,000 shares authorized, 0 shares issued and outstanding at June 30, 2011 and December 31, 2010, respectively |
0 |
| Common stock, $0.001 par value; 100,000,000 shares authorized, 35,850,658 and 35,011,423 shares issued and outstanding at June 30, 2011 and December 31, 2010, respectively |
41K |
| Additional paid-in capital |
342.89M |
| Accumulated other comprehensive loss |
-3.57M |
| Retained earnings |
214.69M |
| Total Emergent BioSolutions Inc. stockholders' equity |
| Noncontrolling interest in subsidiaries |
| Total stockholders' equity |
547.62M |
| Total liabilities and stockholders' equity |
932.03M |
